Pfizer (NYSE:PFE) development partner BioNTech (NASDAQ:BNTX) announces regulatory sign-off in Germany for its Phase 2/3 clinical trial evaluating COVID-19 vaccine candidate BNT162b2.
The companies say more than 25K participants have been enrolled thus far, 83% of the target of 30K across 120 sites globally.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.